Skip to main content
Log in

Pharmacokinetics of total and free valproic acid during monotherapy in infants

  • Original Communications
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Summary

The pharmacokinetics of free and total valproic acid (VPA) in plasma and whole blood after oral administration during steady state was investigated in seven infants (mean age 10.7 months) receiving monotherapy. The VPA concentrations in whole blood closely followed those in plasma but at a reduced level. A positive correlation was found between dose and mean plasma concentration (r=0.71). Mean terminal half-lives were similar in plasma and whole blood (12.5 and 15.5 h, respectively), but were considerably longer than for free VPA (6.4 and 6.5 h, respectively; P<0.01). There was a significant decrease in half-lives with increasing age (P<0.05). Plasma and whole blood clearance for total VPA was higher than reported in older infants and adults (17.8 and 28.9 ml/kg per hour) and was considerably higher for free VPA (127.6 and 188.8 ml/kg per hour, respectively). The increase in clearance compared with that in older subjects is well in concordance with a lower protein binding of VPA (mean 85.3%). Of special importance is that the percentage of unbound VPA increased with increasing concentrations of total VPA. The fraction of unbound VPA in plasma increased even more in subjects with low albumin concentrations (P<0.01).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Bowdle TA, Patel IH, Levy RH, Wilensky AJ (1980) Valproic acid dosage and plasma protein binding and clearance. Clin Pharmacol Ther 28:486–492

    Google Scholar 

  2. Bruni J, Wilder BJ, Willmore LJ, Perchalski RJ, Villarreal HJ (1978) Steady-state kinetics of valproic acid in epileptic patients. Clin Pharmacol Ther 24:324–332

    Google Scholar 

  3. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Molin KA, Menander KB (1987) Valproic acid hepatic fatalities: a retrospective review. Neurology 37:379–385

    Google Scholar 

  4. Ehrnebo M, Agurell S, Boréus LO, Gordon E, Lönnroth U (1974) Pentazocine binding to blood cells and plasma proteins. Clin Pharmacol Ther 16:434–439

    Google Scholar 

  5. Gamstorp I (1985) Paediatric neurology, 2nd edn. Butterworth, London, pp 114–117

    Google Scholar 

  6. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Dekker, New York

    Google Scholar 

  7. Gugler R, Meuller G (1978) Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease. Br J Clin Pharmacol 5:441–446

    Google Scholar 

  8. Herngren L, Nergardh A (1988) Pharmacokinetics of free and total sodium valproate in adolescents and young adults during maintenance therapy. J Neurol 235:491–495

    Google Scholar 

  9. Kilpatrick CJ, Bury RW, Fullinfaw RO, Moulds RFW (1987) Plasma concentrations of unbound valproate and the management of epilepsy. Aust NZ J Med 17:574–579

    Google Scholar 

  10. Kriel RL, Cloyd JC, Green KH, Sawchuk RJ, Lockman LA, Eggerth R (1979) The pharmacokinetics of valproic acid in children. Ann Neurol 6:179

    Google Scholar 

  11. Levy RH, Shen DD (1989) Valproate, Absorption, distribution and excretion. In: Levy RH, Dreifuss FE, Mattson RH, Meldrum BS, Penry JK (eds) Antiepileptic drugs. Raven Press, New York, pp 583–599

    Google Scholar 

  12. Lewandowski C, Klug S, Nau H, Neubert D (1986) Pharmacokinetic aspects of drug effects in vitro: effects of serum protein binding on concentration and teratogenicity of valproic acid and 2-en-valproic acid in whole embryos in culture. Arch Toxicol 58:239–242

    Google Scholar 

  13. Lundberg B, Nergårdh A, Boréus LO (1982) Plasma concentrations of valproate during maintenance therapy in epileptic children. J Neurol 228:133–141

    Google Scholar 

  14. Riva R, Albani F, Cortelli P, Gobbi G, Perucca E, Baruzzi A (1983) Diurnal fluctuations in free and total plasma concentrations of valproic acid at steady state in epileptic patients. Ther Drug Monit 5:191–196

    Google Scholar 

  15. Riva R, Albani F, Franzoni E, Perucca E, Santucci M, Baruzzi A (1983) Valproic acid free fraction in epileptic children under chronic monotherapy. Ther Drug Monit 5:197–200

    Google Scholar 

  16. Riva R, Albani F, Contin M, Baruzzi A, Altomare M, Merlini GP, Perucca E (1984) Mechanism of altered drug binding to serum proteins in pregnant women: studies with valproic acid. Ther Drug Monit 6:25–30

    Google Scholar 

  17. Rowland M, Tozer TN (1989) Integration with kinetics. Clinical pharmacokinetics, 2nd edn. Lea & Febiger, Philadelphia, pp 177–193

    Google Scholar 

  18. Siemes H, Spohr HL, Michael T, Nau H (1988) Therapy of infantile spasms with valproate: results of a prospective study. Epilepsia 29:553–560

    Google Scholar 

  19. Tarasidis CG, Garnett WR, Kline BJ, Pellock JM (1986) Influence of tube type, storage time, and temperature on the total and free concentration of valproic acid. Ther Drug Monit 8:373–376

    Google Scholar 

  20. Zimmerman HJ, Ishak KG (1982) Valproate-induced hepatic injury. Analysis of 23 fatal cases. Hepatology 2:591–598

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Herngren, L., Lundberg, B. & Nerg»rdh, A. Pharmacokinetics of total and free valproic acid during monotherapy in infants. J Neurol 238, 315–319 (1991). https://doi.org/10.1007/BF00315328

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00315328

Key words

Navigation